NCT02287012|Completed
Loading search results
Sponsor study identifier
observational
248
0 countries
N/A
Study Start
October 2013
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2015
Actual (reported)Study Completion
October 2015
Actual (reported)This study aims to observe the effects of the availability of plerixafor on the time and effort associated with autologous peripheral blood stem cell collection.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2015
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 2013
Date type not reportedThis date has not been verified as actual or estimated.
November 3, 2014
Actual (reported)November 10, 2014
Actual (reported)June 2015
Actual (reported)October 2015
Actual (reported)Type, duration and length of administration of mobilizing agents
Number of visits for administration of mobilizing agents Duration (days) of administration of mobilizing agents Type of agents used as mobilizing agents
one week
Number and length of apheresis sessions and number of collected stem cells
Number of apheresis sessions Number of hours of apheresis sessions Attainment of CD34+ cells target (yes, no) Number of days until CD34+ target level is met
one week
The first era (Pre-Plerixafor era) will be defined as a two year period immediately preceding commercialization of plerixafor in Europe, (e.g., June 1, 2007 through June 1, 2009).
The second era (Plerixafor era) will be defined as July 1, 2010 through July 1, 2012).
The actual apheresis events will be measured in consecutive patients scheduled to be candidates for peripheral blood stem mobilization in the apheresis area of the hospital. Each apheresis will be considered as one event . Should the patient receive more than 1 apheresis, each apheresis will be considered as one different event.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
The study will consist of two parts: I. Retrospective study: A medical record review will be conducted covering 200 patients file undergoing peripheral blood stem cell mobilization in different European centers. Patients will be selected from each of centers, evenly divided between two eras: 1) prior to approval of plerixafor= Pre-P era (July 2009); and 2) after approval of plerixafor= P era . II. Prospective study :Time/Motion evaluation of actual apheresis - 20 events each center
Mohamad Mohty, MD, PhD
Hôpital Saint-Antoine
248 participants (actual enrollment reported by the registry).
First Submitted
November 3, 2014
First Posted
November 10, 2014
Study Start
October 2013
Date type not reportedThis date has not been verified as actual or estimated.
Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas
Contact the study team to confirm eligibility.
Primary Completion
June 2015
Actual (reported)Study Completion
October 2015
Actual (reported)Last Updated
October 7, 2016
Record last verified: 2016-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: